Clover Health Investments Corp (NASDAQ:CLOV) shares traded -7.08% lower at $3.41 on Wall Street last session.
CLOV stock price is now -1.71% away from the 50-day moving average and 91.23% away from the 200-day moving average. The market capitalization of the company currently stands at $1.58B.
With the price target of $4, UBS recently initiated with Neutral rating for Clover Health Investments Corp (NASDAQ: CLOV). On February 02, 2022, Cowen Upgraded its previous ‘Underperform’ rating to ‘Market Perform’ on the stock reducing its target price from $7 to quote $3, while ‘Canaccord Genuity’ rates the stock as ‘Buy’
In other news, Garipalli Vivek, Director bought 531,700 shares of the company’s stock on Aug 09 ’24. The stock was bought for $999,596 at an average price of $1.88. Upon completion of the transaction, the Director now directly owns 1,409,267 shares in the company, valued at $4.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 17 ’24, Director Garipalli Vivek bought 877,567 shares of the business’s stock. A total of $1,000,426 was incurred on buying the stock at an average price of $1.14. This leaves the insider owning 877,567 shares of the company worth $2.99 million. A total of 25.03% of the company’s stock is owned by insiders.
During the past 12 months, Clover Health Investments Corp has had a low of $0.61 and a high of $4.71. The fifty day moving average price for CLOV is $3.4693 and a two-hundred day moving average price translates $1.783235 for the stock.
The latest earnings results from Clover Health Investments Corp (NASDAQ: CLOV) was released for 2024-09-30. The net profit margin was -5.94% and return on equity was -28.69% for CLOV. The company reported revenue of $356.26 million for the quarter, compared to $320.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.28 percent.
